/

Sociétés

Pe

Non vérifié

PeptiDream Inc.

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueSantéScience

8 communiqués de presse

Voir tous les communiqués de presse

11/06/2026

Industrie

Science

Médecine nucléaire

Biotechnologie

Industrie pharmaceutique

Oncologie

Santé

Médecine - Divers

PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer

Source

PeptiDream Inc.

Émetteur

1.00

0

11/06/2026

Industrie

Science

Médecine - Divers

Biotechnologie

Médecine nucléaire

Industrie pharmaceutique

Vitrines/Shopping

Santé

Oncologie

PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

Source

PeptiDream Inc.

Émetteur

1.00

0

20/04/2026

Industrie

Santé

VIH, SIDA et maladies auto-immunes

Médecine - Divers

Médecine nucléaire

Industrie pharmaceutique

Biotechnologie

PeptiDream Announces the Initiation of Phase 1 Clinical Trial by Its Collaboration Partner

Source

PeptiDream Inc.

Émetteur

1.00

0

18/12/2025

Industrie

Biotechnologie

Santé

Science

Industrie pharmaceutique

PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues

Source

PeptiDream Inc.

Émetteur

1.00

0

17/12/2025

Industrie

Biotechnologie

Santé

Science

Industrie pharmaceutique

PeptiDream Announces Promising Pre-Clinical Results of Proprietary Oral IL-17A and IL-17F Dual Inhibitor with Biologic-Like Efficacy for the Treatment of Psoriasis

Source

PeptiDream Inc.

Émetteur

1.00

0

28/03/2025

Industrie

Santé Publique

Médecine - Divers

Biologie

Biotechnologie

Médecine nucléaire

Industrie pharmaceutique

Santé

Oncologie

National Cancer Center Japan and PeptiDream: New Radiopharmaceuticals for Renal Cell Carcinoma

Source

PeptiDream Inc.

Émetteur

1.00

0

12/12/2024

Industrie

Oncologie

Santé

Santé Publique

Science

Industrie pharmaceutique

Biotechnologie

PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer

Source

PeptiDream Inc.

Émetteur

1.00

0

12/12/2024

Industrie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment

Source

PeptiDream Inc.

Émetteur

1.00

0

Followers

0

Compatibilité

0